Browse the evidence

Tirzepatide (5-15 mg once weekly) produces superior weight loss (16-22.5% mean reduction) compared to placebo and other GLP-1 RAs by acting as a dual GLP-1 and GIP receptor agonist.

Tirzepatide is a once-weekly injection that significantly reduces body weight (16-22.5%) in adults with overweight or obesity. It works by mimicking two gut hormones (GLP-1 and GIP) to increase satiety and reduce food intake. Treatment starts at a low dose (2.5 mg) and increases every 4 weeks to minimize side effects like nausea. It is most effective when combined with lifestyle changes, including a caloric deficit and regular physical activity.

Once-weekly subcutaneous semaglutide 2.4 mg induces greater weight loss from baseline than placebo and once-daily liraglutide 3.0 mg in patients with overweight or obesity, with or without type 2 diabetes.

Semaglutide 2.4 mg is a once-weekly injection approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with comorbidities. It is taken alongside a calorie-controlled diet and increased physical activity. The dose starts low (0.25 mg) and increases every 4 weeks to 2.4 mg to minimize side effects. It is currently the most efficacious medication for weight loss, producing double-digit percentage body weight reductions over 1-2 years, superior to placebo and once-daily liraglutide.

Total Diet Replacement (TDR) using meal replacements in very-low-calorie diets (VLCDs) produces significantly greater weight loss (average >10 kg over 12 months) and superior diabetes remission rates compared to usual care or food-based diets.

If you have obesity or Type 2 Diabetes, using Total Diet Replacement (TDR) with meal replacements for 3-5 months, followed by maintenance with 1-2 meal replacements daily, is a clinically proven strategy. It leads to significantly more weight loss (average 10kg+) and higher diabetes remission rates than standard advice. Ensure you work with a healthcare provider for medical supervision, especially during the initial very-low-calorie phase.

Meal replacement interventions improve cardiometabolic health outcomes, including glycemic control, blood pressure, lipids, and liver fat, often independent of or proportional to the degree of weight loss.

Using meal replacements to lose weight not only helps you shed pounds but also significantly improves your blood sugar, blood pressure, and liver health. This is especially true if you have Type 2 Diabetes, where significant weight loss can lead to remission.

Once-weekly subcutaneous semaglutide 2.4 mg, used as an adjunct to lifestyle intervention, significantly improves cardiometabolic risk factors—including waist circumference, HbA1c, blood pressure, and lipid profiles—in adults with overweight or obesity, with or without type 2 diabetes.

If you have obesity or overweight with related health risks, once-weekly semaglutide 2.4 mg, combined with a calorie-reduced diet and regular exercise, significantly improves key health markers like blood pressure, blood sugar, and cholesterol. This treatment is most effective when used long-term, as stopping it can reverse these benefits.

High-dose GLP-1 receptor agonists (semaglutide 2.4 mg and tirzepatide 15 mg) produce substantial, clinically significant weight loss in adults with obesity, with tirzepatide demonstrating superior efficacy compared to other agents.

If you have obesity, high-dose GLP-1 medications like semaglutide (2.4 mg weekly) or tirzepatide (15 mg weekly) are significantly more effective for weight loss than lifestyle changes alone. Tirzepatide showed the highest efficacy in this review. These treatments work by targeting hormonal pathways that regulate hunger and satiety, and they are most effective when combined with standard lifestyle counseling.

Tirzepatide administered once weekly produces significant weight loss (mean difference -16.32% body weight) and improves cardiometabolic markers (BMI, waist circumference, lipids, blood pressure) in patients with overweight or obesity without diabetes mellitus, though it carries a significantly elevated risk of gastrointestinal side effects.

For individuals with overweight or obesity without diabetes, tirzepatide is a highly effective pharmacological intervention for weight loss, producing greater reductions than GLP-1 RAs like semaglutide. It also improves blood pressure, lipids, and glycemic control. However, patients must be prepared for a high likelihood of gastrointestinal side effects (nausea, vomiting, diarrhea), which can lead to discontinuation. The overall risk of serious adverse events is not significantly higher than placebo, but the burden of GI symptoms is a key consideration for adherence.

GLP-1 receptor agonists significantly increase the likelihood of achieving weight loss compared to placebo, with tirzepatide and semaglutide demonstrating the highest relative efficacy among evaluated agents.

If you have obesity or overweight with related health issues, GLP-1 receptor agonists like semaglutide or tirzepatide are highly effective pharmacological options. They work by mimicking a hormone that reduces hunger and slows digestion. Clinical data shows they significantly increase the chance of losing weight compared to placebo, with tirzepatide and semaglutide showing the best results. These medications are FDA-approved for chronic weight management and should be used in combination with lifestyle changes.

Abdominal obesity (measured by waist circumference) is the most critical underlying risk factor for metabolic syndrome, serving as a strong proxy for insulin resistance and visceral fat accumulation.

Track your waist circumference, not just your weight. For men, a waist over 40 inches (102 cm) and for women over 35 inches (88 cm) indicates high risk. For Asian populations, lower thresholds (35 inches for men, 31.5 inches for women) apply. Reducing waist size is the most effective way to lower your risk of heart disease and diabetes.

Progressive resistance training protocols must manipulate variables such as intensity, volume, and exercise selection to stimulate adaptation toward specific goals like strength, hypertrophy, or power.

To build strength or muscle, you must progressively challenge your body. Start with 8-12 reps per set. Once you can do 1-2 extra reps comfortably, increase the weight by 2-10%. Do 2-3 sets if you are new, but move to 3-4+ sets if you have been training for months. Prioritize compound movements like squats and presses.

For patients with type 2 diabetes and chronic kidney disease (CKD), SGLT2 inhibitors are recommended to reduce CKD progression, with GLP-1 receptor agonists as an alternative if SGLT2 inhibitors are contraindicated.

If you have diabetes and kidney disease, ask your doctor about SGLT2 inhibitors (like empagliflozin) or GLP-1 agonists (like liraglutide). These drugs have been proven to slow down kidney damage and reduce the risk of needing dialysis, offering benefits beyond just lowering blood sugar.

Adherence to a low-risk lifestyle profile (BMI <25, high cereal fiber/polyunsaturated fat, low trans fat/glycemic load, moderate-to-vigorous exercise, no smoking, moderate alcohol) reduces the risk of type 2 diabetes by approximately 91% compared to non-adherent women.

To drastically lower your risk of type 2 diabetes, focus on maintaining a healthy weight (BMI under 25), eating a diet rich in fiber and healthy fats while avoiding trans fats and high-glycemic foods, exercising for at least 30 minutes daily, not smoking, and if you drink, do so moderately. You don't need to be perfect; even adhering to three of these habits can prevent the majority of diabetes cases.

Excess visceral adipose tissue (VAT) is an independent risk factor for cardiovascular disease and mortality, regardless of overall body mass index (BMI).

Focus on waist circumference, not just weight. If your waist is large, your visceral fat is likely high, which drives heart disease risk even if your BMI is normal. Measure your waist and aim to reduce it through lifestyle changes.

Adhering to the AHA 2006 Diet and Lifestyle Recommendations substantially reduces the risk of developing cardiovascular disease (CVD) by addressing multiple risk factors including blood pressure, lipid profiles, and body weight.

To protect your heart, focus on your overall diet rather than just one 'superfood.' Eat plenty of vegetables, fruits, and whole grains, and choose lean proteins like fish at least twice a week. Limit saturated fats to less than 7% of your calories and avoid trans fats. Stay physically active for at least 30 minutes most days. These combined lifestyle changes offer the best protection against heart disease.

Achieving and maintaining a healthy body weight (BMI 18.5-24.9 kg/m2) through calorie balance and physical activity is critical for reducing CVD risk, with prevention of weight gain being more effective than weight loss.

Focus on maintaining a healthy weight (BMI 18.5-24.9) by balancing what you eat with how much you move. Preventing weight gain is easier and more effective than losing it later. If you smoke, quit; the risk of weight gain is not a valid reason to continue smoking.

Increasing daily servings of potato chips, potatoes, sugar-sweetened beverages, unprocessed red meats, and processed meats is independently associated with greater long-term weight gain, whereas increasing servings of vegetables, whole grains, fruits, nuts, and yogurt is associated with less weight gain.

To prevent long-term weight gain, focus on specific food swaps rather than just counting calories. Reduce daily servings of potato chips, french fries, sugar-sweetened beverages, and processed meats. Instead, increase your intake of yogurt, nuts, fruits, whole grains, and vegetables. These changes are independently associated with less weight gain, likely because they are more satiating and displace less healthy options.

Increases in physical activity are associated with less long-term weight gain, whereas absolute levels of physical activity are not associated with weight change.

To prevent long-term weight gain, focus on *increasing* your physical activity over time, not just maintaining your current level. The study found that absolute activity levels didn't predict weight change, but increases in activity were associated with less weight gain.

Replacing 5% of energy intake from saturated fat with unsaturated fats reduces the risk of coronary heart disease in women by 42%, whereas replacing it with carbohydrates yields a smaller benefit.

To lower your risk of heart disease, focus on swapping the type of fat you eat rather than just cutting down on fat overall. Specifically, replace 5% of your daily calories from saturated fats (found in red meat, butter, full-fat dairy) with unsaturated fats (found in olive oil, nuts, avocados, fish). This specific swap is linked to a significant 42% reduction in heart disease risk.

Replacing 2% of energy intake from trans unsaturated fat with unhydrogenated unsaturated fats reduces the risk of coronary heart disease in women by 53%.

Eliminate trans fats from your diet to significantly lower your heart disease risk. Specifically, replace just 2% of your daily calories from trans fats (found in some fried foods and baked goods made with partially hydrogenated oils) with unsaturated fats (like those in olive oil, nuts, or fish). This specific swap is linked to a 53% reduction in heart disease risk.

Maintaining a body-mass index (BMI) between 19 and 25 is associated with the lowest mortality rates and reduced risk of chronic diseases, whereas weight gain during adulthood significantly increases the risk of type 2 diabetes, hypertension, and coronary heart disease.

Aim to keep your BMI between 19 and 25. Do not accept gradual weight gain as 'normal' aging. If you gain 10 pounds after reaching adult height, intervene immediately with diet and activity changes to prevent long-term metabolic damage.

Brisk walking (≥3 hours/week) reduces the risk of coronary events in women by approximately 35% compared to sedentary levels, achieving risk reductions similar to vigorous exercise when total energy expenditure (MET-hours) is matched.

To significantly lower your risk of heart disease, aim for at least three hours of brisk walking per week. You do not need to run or perform high-intensity workouts to get these benefits; walking fast enough to raise your heart rate (brisk pace) is sufficient. This is a highly accessible, low-barrier strategy for cardiovascular health.

Consuming 30–60 g/h of carbohydrate during exercise lasting longer than one hour improves performance by sparing muscle glycogen and maintaining blood glucose, while intakes up to 90 g/h using multiple transportable carbohydrates (glucose:fructose 2:1) maximize oxidation rates for ultra-endurance events.

For any event lasting over an hour, consume 30-60 grams of carbohydrates per hour. If the event is longer than 2.5 hours, aim for up to 90 grams per hour by using products that mix glucose and fructose (look for a 2:1 ratio). This maximizes your energy delivery and performance. Practice this in training to ensure your stomach can handle it.

Replacing saturated and trans fats with unsaturated fats (monounsaturated or polyunsaturated) significantly reduces the risk of coronary heart disease, whereas simply reducing total fat intake without regard to fat type does not provide the same benefit.

Stop focusing on 'low-fat' labels. Instead, swap high-saturated fat foods (like fatty meats and full-fat dairy) and trans fats (like some baked goods) with unsaturated fats (like olive oil, nuts, and fish). This specific swap is proven to lower heart disease risk more effectively than just eating less fat overall.

Trans fatty acids significantly increase the risk of coronary heart disease by raising LDL cholesterol, lowering HDL cholesterol, increasing lipoprotein(a), and promoting insulin resistance.

Avoid trans fats completely. They are found in partially hydrogenated oils, often in baked goods, crackers, and fried foods. Eliminating them significantly lowers heart disease risk.